Cardiac Senescence and Heart Failure: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Cardiac senescence, characterized by irreversible cellular aging processes within the myocardium, plays a pivotal role in the pathogenesis and progression of heart failure. This review synthesizes current evidence on the molecular mechanisms underlying cardiac senescence, its contribution to heart failure epidemiology, risk stratification, clinical presentation, diagnostic paradigms, and therapeutic management. It further explores recent advances in anti-senescence therapies and guideline-oriented recommendations, providing clinicians and researchers with a comprehensive, up-to-date resource on this evolving topic.

Introduction

Cardiac senescence is an emerging concept in cardiovascular medicine, referring to the accumulation of aged, dysfunctional cardiomyocytes and stromal cells in the heart. This process is intricately associated with age-related cardiovascular diseases, most notably heart failure, which remains a leading cause of morbidity and mortality worldwide. Understanding the interplay between cellular senescence and myocardial dysfunction is essential for developing innovative strategies to prevent and manage heart failure in the aging population. Recent research has highlighted the clinical importance of senescence-associated pathways, providing new insights into the mechanisms of cardiac remodeling, inflammation, and repair.

Epidemiology / Disease Burden

The global prevalence of heart failure is estimated to exceed 64 million individuals, with a disproportionate burden among older adults. Epidemiological studies consistently demonstrate that advancing age is the strongest risk factor for heart failure, and this correlation is partly attributed to the accumulation of senescent cells within cardiac tissue. Population-based data reveal that the incidence of heart failure rises exponentially after the age of 65, paralleling increases in biomarkers of cellular senescence. The societal and economic impact of heart failure is profound, with recurrent hospitalizations, reduced quality of life, and escalating healthcare costs.

Pathophysiology

Cardiac senescence is driven by a combination of replicative and stress-induced cellular aging. Mechanistically, telomere attrition, DNA damage, mitochondrial dysfunction, and oxidative stress converge to induce a senescent phenotype in cardiomyocytes and cardiac fibroblasts. Senescent cells secrete pro-inflammatory cytokines, chemokines, and matrix metalloproteinases a collective phenomenon described as the senescence-associated secretory phenotype (SASP). The SASP fosters maladaptive remodeling, fibrosis, and impaired ventricular function. These changes promote diastolic and systolic dysfunction, laying a biological foundation for heart failure. Impaired regenerative capacity and altered intercellular communication further exacerbate myocardial decline.

Risk Factors

Key risk factors for cardiac senescence and subsequent heart failure include chronological aging, hypertension, diabetes mellitus, dyslipidemia, obesity, and chronic inflammatory states. Genetic predispositions, such as mutations affecting telomerase activity or mitochondrial function, also enhance susceptibility. Lifestyle factors including sedentary behavior, poor dietary patterns, and tobacco use accelerate cellular aging processes. Emerging data suggest that chronic kidney disease, sleep disorders, and exposure to environmental toxins may contribute to premature cardiac senescence.

Clinical Features

The clinical manifestations of heart failure driven by senescence are often indistinguishable from other etiologies but may exhibit unique features in the elderly. Patients typically present with exertional dyspnea, fatigue, reduced exercise tolerance, peripheral edema, and signs of fluid overload. In older adults, the syndrome may be complicated by frailty, sarcopenia, cognitive decline, and increased vulnerability to stressors. A high prevalence of preserved ejection fraction (HFpEF) is observed in senescence-associated heart failure, reflecting the predominant role of myocardial stiffness and impaired relaxation.

Diagnosis

Diagnostic evaluation integrates clinical assessment, laboratory biomarkers, and advanced imaging. Natriuretic peptides (BNP, NT-proBNP) remain central to heart failure diagnosis but are influenced by age and renal function. Novel biomarkers, such as circulating senescence markers (e.g., p16INK4a, SASP cytokines), are under investigation for their diagnostic and prognostic value. Echocardiography provides essential information on chamber size, wall thickness, diastolic function, and ejection fraction. Cardiac MRI offers superior tissue characterization, detecting fibrosis and remodeling associated with senescence. Endomyocardial biopsy is rarely indicated but may reveal senescent cell accumulation in research settings.

Treatment & Management

Management of heart failure in the context of cardiac senescence aligns with general heart failure guidelines but requires special consideration of frailty, comorbidities, and polypharmacy in older adults. Pharmacologic therapy includes renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and, for select patients, SGLT2 inhibitors. Non-pharmacologic measures such as dietary sodium restriction, exercise rehabilitation, and close monitoring are crucial. Management of comorbid conditions, optimization of blood pressure, and prevention of hospital readmissions are key components. Device therapy (ICD, CRT) may benefit select patients but must be tailored to functional status and life expectancy.

Recent Advances / Emerging Therapies

Recent translational research has focused on senolytic agents compounds that selectively eliminate senescent cells. Preclinical studies indicate that senolytics (e.g., dasatinib, quercetin) improve cardiac function and reduce fibrosis in aged animal models. Other promising strategies include NAD+ boosters, telomerase activators, and interventions targeting mitochondrial resilience. Clinical trials are underway to assess the safety and efficacy of these therapies in humans. Additionally, efforts to modulate the SASP and enhance endogenous cardiac regeneration through stem cell-based therapies are being explored, heralding a new era in the management of age-related heart failure.

Guideline Recommendations

Current heart failure management guidelines from major societies (AHA/ACC/HFSA, ESC) emphasize a patient-centered approach, with special attention to the geriatric population. While specific recommendations for senescence-targeted therapies await further evidence, clinicians are encouraged to recognize the unique challenges associated with aging and heart failure. Comprehensive geriatric assessment, multidisciplinary care coordination, and shared decision-making are endorsed. Emerging evidence may soon inform future guideline updates as the field of cardiac senescence advances.

Conclusion

Cardiac senescence is a critical driver of heart failure and a promising target for therapeutic intervention. Advances in understanding the molecular pathways of cellular aging have unveiled new opportunities for clinical translation. While standard heart failure therapies remain foundational, the integration of senolytic and regenerative approaches may revolutionize care for older adults in the coming years. Ongoing research and multidisciplinary collaboration are essential to translate these insights into improved outcomes for patients with heart failure.